Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 15/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396909 | 1.00 | L3MBTL1 (0.47) | L3MBTL1HIF1AEGLN1TSHRKDM4E | |
| SCHEMBL2384067 | 0.90 | L3MBTL1 (0.52) | L3MBTL1HIF1AEGLN1KDM4EALDH1A1 | |
| SCHEMBL12254374 | 0.90 | L3MBTL1 (0.52) | L3MBTL1HIF1AEGLN1KDM4EALDH1A1 | |
| SCHEMBL2384068 | 0.90 | L3MBTL1 (0.52) | L3MBTL1HIF1AEGLN1KDM4EALDH1A1 | |
| SCHEMBL12254565 | 0.89 | L3MBTL1 (0.48) | L3MBTL1HIF1AEGLN1KDM4EALDH1A1 | |
| SCHEMBL12254430 | 0.89 | L3MBTL1 (0.48) | L3MBTL1HIF1AEGLN1KDM4EALDH1A1 | |
| SCHEMBL2384504 | 0.86 | HIF1A (0.52) | L3MBTL1HIF1AEGLN1 | |
| SCHEMBL2384507 | 0.86 | HIF1A (0.52) | L3MBTL1HIF1AEGLN1 | |
| SCHEMBL2385667 | 0.85 | L3MBTL1 (0.50) | L3MBTL1HIF1AEGLN1TSHRKDM4E | |
| SCHEMBL2385668 | 0.85 | L3MBTL1 (0.50) | L3MBTL1HIF1AEGLN1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | L3MBTL1 4035/4885HIF1A 4/4885EGLN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.